Supplementary Figure 2From: Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administrationBinding affinity of matrix metalloproteinase (MMP) peptides to purified RT1.BL. The binding affinity of the competitor peptides (MMP peptides) was tested in a competitive MHC class II peptide binding assay in a dose range of 0–256 μM. * IC50, concentration of competitor peptide (μM) resulting in 50% inhibition of the binding of marker peptide to RT1.BL, as evaluated by Molecular Analyst Software (see Supplementary Materials and methods).Back to article page